Cargando…

Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer

Neoadjuvant chemotherapy (NACT) before radical hysterectomy has been widely used for locally advanced cervical cancer (LACC); However, its efficacy is yet to be determined. METHODS: Effective and predictive biomarkers, which may aid in predicting the chemotherapy responses, were explored in this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ke, Hu, Min, Yang, Runfeng, Liu, Jing, Zeng, Pingfan, Zhao, Tingkuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194672/
https://www.ncbi.nlm.nih.gov/pubmed/37335690
http://dx.doi.org/10.1097/MD.0000000000033820
_version_ 1785044064208420864
author Zhao, Ke
Hu, Min
Yang, Runfeng
Liu, Jing
Zeng, Pingfan
Zhao, Tingkuan
author_facet Zhao, Ke
Hu, Min
Yang, Runfeng
Liu, Jing
Zeng, Pingfan
Zhao, Tingkuan
author_sort Zhao, Ke
collection PubMed
description Neoadjuvant chemotherapy (NACT) before radical hysterectomy has been widely used for locally advanced cervical cancer (LACC); However, its efficacy is yet to be determined. METHODS: Effective and predictive biomarkers, which may aid in predicting the chemotherapy responses, were explored in this study. Initially, the expression of HIF-1α, VEGF-A, and Ki67 was detected in 42 paired (pre-NACT and post-NACT) LACC tissues, as well as 40 nonneoplastic cervical epithelial tissues by immunohistochemistry. Then, the correlation of the expression of HIF-1α, VEGF-A, Ki67 with the efficacy of NACT, as well as factors that affect the efficacy of NACT was analyzed. RESULTS: A clinical response occurred in 66.7% (28/42) of the patients, including 57.1% (16/28) with a complete response and 42.9% (12/28) with a partial response; While 33.33% (14/42) were non-responders, including 42.9% (6/14) with stable disease and 57.1% (8/14) with progressive disease. HIF-1α, VEGF-A, and Ki67 were overexpressed in LACC tissues compared to nonneoplastic tissues (P < .01, respectively); While the expression of HIF-1α, VEGF-A, and Ki67 was significantly decreased after NACT (P < .01, respectively). What’s more, in the response group, HIF-1α, VEGF-A, and Ki67 expression were significantly decreased after chemotherapy in the post-chemotherapy cervical cancer tissues compared with the pre-chemotherapy cervical cancer tissues (all P < .05). Additionally, patients with lower histological grade and lower expression of HIF-1α, VEGF-A, and Ki67 were more responsive to NACT (P < .05, respectively); Moreover, the histological grade [P = .025, HR (95% CI): 0.133 (0.023–0.777)], HIF-1α [P = .019, HR (95% CI): 0.599 (0.390–0.918)], and Ki67 [P = .036, HR (95% CI): 0.946 (0898–0.996)] were independent risk factors affecting the efficacy of NACT in LACC. CONCLUSION: Expression of HIF-1α, VEGF-A, and Ki67 were significantly decreased after NACT, and decreasing expression of HIF-1α, VEGF-A, and Ki67 were related to good response to NACT, suggesting HIF-1α, VEGF-A, and Ki67 may be implicated in evaluating the efficacy of NACT in LACC.
format Online
Article
Text
id pubmed-10194672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101946722023-05-19 Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer Zhao, Ke Hu, Min Yang, Runfeng Liu, Jing Zeng, Pingfan Zhao, Tingkuan Medicine (Baltimore) 5600 Neoadjuvant chemotherapy (NACT) before radical hysterectomy has been widely used for locally advanced cervical cancer (LACC); However, its efficacy is yet to be determined. METHODS: Effective and predictive biomarkers, which may aid in predicting the chemotherapy responses, were explored in this study. Initially, the expression of HIF-1α, VEGF-A, and Ki67 was detected in 42 paired (pre-NACT and post-NACT) LACC tissues, as well as 40 nonneoplastic cervical epithelial tissues by immunohistochemistry. Then, the correlation of the expression of HIF-1α, VEGF-A, Ki67 with the efficacy of NACT, as well as factors that affect the efficacy of NACT was analyzed. RESULTS: A clinical response occurred in 66.7% (28/42) of the patients, including 57.1% (16/28) with a complete response and 42.9% (12/28) with a partial response; While 33.33% (14/42) were non-responders, including 42.9% (6/14) with stable disease and 57.1% (8/14) with progressive disease. HIF-1α, VEGF-A, and Ki67 were overexpressed in LACC tissues compared to nonneoplastic tissues (P < .01, respectively); While the expression of HIF-1α, VEGF-A, and Ki67 was significantly decreased after NACT (P < .01, respectively). What’s more, in the response group, HIF-1α, VEGF-A, and Ki67 expression were significantly decreased after chemotherapy in the post-chemotherapy cervical cancer tissues compared with the pre-chemotherapy cervical cancer tissues (all P < .05). Additionally, patients with lower histological grade and lower expression of HIF-1α, VEGF-A, and Ki67 were more responsive to NACT (P < .05, respectively); Moreover, the histological grade [P = .025, HR (95% CI): 0.133 (0.023–0.777)], HIF-1α [P = .019, HR (95% CI): 0.599 (0.390–0.918)], and Ki67 [P = .036, HR (95% CI): 0.946 (0898–0.996)] were independent risk factors affecting the efficacy of NACT in LACC. CONCLUSION: Expression of HIF-1α, VEGF-A, and Ki67 were significantly decreased after NACT, and decreasing expression of HIF-1α, VEGF-A, and Ki67 were related to good response to NACT, suggesting HIF-1α, VEGF-A, and Ki67 may be implicated in evaluating the efficacy of NACT in LACC. Lippincott Williams & Wilkins 2023-05-17 /pmc/articles/PMC10194672/ /pubmed/37335690 http://dx.doi.org/10.1097/MD.0000000000033820 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5600
Zhao, Ke
Hu, Min
Yang, Runfeng
Liu, Jing
Zeng, Pingfan
Zhao, Tingkuan
Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title_full Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title_fullStr Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title_full_unstemmed Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title_short Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
title_sort decreasing expression of hif-1α, vegf-a, and ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer
topic 5600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194672/
https://www.ncbi.nlm.nih.gov/pubmed/37335690
http://dx.doi.org/10.1097/MD.0000000000033820
work_keys_str_mv AT zhaoke decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer
AT humin decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer
AT yangrunfeng decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer
AT liujing decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer
AT zengpingfan decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer
AT zhaotingkuan decreasingexpressionofhif1avegfaandki67withefficacyofneoadjuvanttherapyinlocallyadvancedcervicalcancer